Cointime

ADARx Pharmaceuticals

company

About

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

  • 1 - 10

Highlights

Total Funding Amount
$121M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$75M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored.

It was founded in 2019 and is headquartered in San Diego, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$121M
ADARx Pharmaceuticals has raised a total of $121M in funding over 2 rounds. Their latest funding was raised on Jan 20, 2023 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 20, 2023 Series B $46M 1 — — Detail
Sep 8, 2021 Series B $75M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
ADARx Pharmaceuticals is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures — Series B
Cointime
เนื้อหา
บริษัท